share_log

藥明巨諾-B：2024中期報告

JW THERAP-B: 2024 INTERIM REPORT

HKEX ·  Sep 26 04:34

Summary by Moomoo AI

藥明巨諾-B公布2024年中期報告，顯示截至2024年6月30日止六個月，公司收入為人民幣86.8百萬元，與上年同期的人民幣87.7百萬元相比保持穩定。該收入主要來自公司的CAR-T免疫治療產品倍諾達®的持續商業化。期內虧損為人民幣240.3百萬元，較去年同期的人民幣380.4百萬元有所減少。研發開支由去年同期的人民幣216.5百萬元減少至人民幣151.0百萬元，主要由於營運效率提升及研發策略優化。銷售開支則由去年同期的人民幣60.2百萬元增加至人民幣76.2百萬元。截至報告期末，公司現金及現金等價物為人民幣869.0百萬元。公司在報告期間進行了多項管理層變動，包括劉敏先生獲委任為行政總裁及執行董事，而Yiping James Li醫生則由行政總裁調任為非執行董事。公司未派發中期股息。
藥明巨諾-B公布2024年中期報告，顯示截至2024年6月30日止六個月，公司收入為人民幣86.8百萬元，與上年同期的人民幣87.7百萬元相比保持穩定。該收入主要來自公司的CAR-T免疫治療產品倍諾達®的持續商業化。期內虧損為人民幣240.3百萬元，較去年同期的人民幣380.4百萬元有所減少。研發開支由去年同期的人民幣216.5百萬元減少至人民幣151.0百萬元，主要由於營運效率提升及研發策略優化。銷售開支則由去年同期的人民幣60.2百萬元增加至人民幣76.2百萬元。截至報告期末，公司現金及現金等價物為人民幣869.0百萬元。公司在報告期間進行了多項管理層變動，包括劉敏先生獲委任為行政總裁及執行董事，而Yiping James Li醫生則由行政總裁調任為非執行董事。公司未派發中期股息。
WuXi AppTec-B announced its mid-year report for 2024, showing that for the six months ended June 30, 2024, the company's revenue was RMB 868 million, stable compared to RMB 877 million in the same period last year. The revenue mainly comes from the continued commercialization of the company's CAR-T immunotherapy product Belenus®. The loss for the period was RMB 240.3 million, a decrease from RMB 380.4 million in the same period last year. Research and development expenses decreased from RMB 216.5 million in the same period last year to RMB 151.0 million, mainly due to operational efficiency improvements and R&D strategy optimization. Sales expenses increased from RMB 60.2 million in the same period last year to RMB 76.2 million. As of the end of the...Show More
WuXi AppTec-B announced its mid-year report for 2024, showing that for the six months ended June 30, 2024, the company's revenue was RMB 868 million, stable compared to RMB 877 million in the same period last year. The revenue mainly comes from the continued commercialization of the company's CAR-T immunotherapy product Belenus®. The loss for the period was RMB 240.3 million, a decrease from RMB 380.4 million in the same period last year. Research and development expenses decreased from RMB 216.5 million in the same period last year to RMB 151.0 million, mainly due to operational efficiency improvements and R&D strategy optimization. Sales expenses increased from RMB 60.2 million in the same period last year to RMB 76.2 million. As of the end of the reporting period, the company's cash and cash equivalents were RMB 869.0 million. The company underwent several management changes during the reporting period, including the appointment of Mr. Liu Min as CEO and executive director, while Dr. Yiping James Li was reassigned from CEO to non-executive director. The company did not declare an interim dividend.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated